Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Efficacy of Erythropoietin Mouthwash in Prevention of Oral Mucositis in Patients Undergoing Autologous Hematopoietic Sct: A Double-Blind, Randomized, Placebocontrolled Trial Publisher Pubmed



Hosseinjani H1 ; Hadjibabaie M1, 2 ; Gholami K1, 2 ; Javadi M1, 2 ; Radfar M1 ; Jahangardrafsanjani Z1 ; Hosseinjani E3 ; Shabani N4 ; Vaezi M5 ; Ghavamzadeh A5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  4. 4. Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Hematology-Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Hematological Oncology Published:2017


Abstract

Oral mucositis (OM) as a complication of high-dose chemotherapy is frequently occurred in hematopoietic stem cell transplantation (HSCT) settings. Erythropoietin (EPO) has anti-inflammatory, antioxidant andwound-healing properties and therefore could have an important role in the prevention of OM. We conducted a double-blind, randomized, placebocontrolled trial to evaluate the EPO mouthwash effect onOMincidence and severity in 80 patients with non-Hodgkin’s lymphoma, Hodgkin disease (HD) or multiple myeloma, undergoing autologous hematopoietic stem cell transplantation. Patients received either EPO mouthwash (50IU/ml, 15ml four times a day) (n = 40) or placebo (n = 40) from the starting day of high-dose chemotherapy until day +14 after transplantation or until the day of discharge from the hospital, whichever occurred first. OM was evaluated daily for 21 days after transplantation or until resolution ofOMaccording toWorld Health Organization oral toxicity scale. The incidence of OM (grades 1–4) in the EPO mouthwash group and control group was significantly different (27.5% vs 77.5%, p<0.001). The mean ± SD of two other parameters of OM including maximum intensity OM score (0.60 ± 1.06 vs 1.67± 1.27) and average intensity OM score (0.47± 0.80 vs 1.28 ± 0.86) was significantly lower in the intervention group (p<0.001).Moreover, themean± SD duration ofOMwas also significantly shorter among the EPO mouthwash recipients (1.92± 3.42 days vs 5.42 ± 3.86 days, P<0.001). Also, the duration of neutropenic fever was significantly shorter in the intervention group (2.12 ± 2.42 days vs 3.95± 4.01days, p = 0.016). It is concluded that EPO mouthwash can reduce the incidence and duration of OM. © 2015 John Wiley & Sons, Ltd.
Experts (# of related papers)
Other Related Docs